AbbVie Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
AbbVie Inc. (ABBV) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements of $1.78 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements · last filed 2026-08-03
- AbbVie Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2026-06-30 was $1.06B, a 23.63% increase year-over-year.
- AbbVie Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2026-03-31 was $722.00M, a 31.51% increase year-over-year.
- AbbVie Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2025-12-31 was $681.00M, a 26.35% increase year-over-year.
- AbbVie Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2025-09-30 was $776.00M, a 33.79% increase year-over-year.
- AbbVie Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2025 was $2.87B, a 43.61% increase from fiscal 2024.
- AbbVie Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2024 was $2.00B, a 23.00% increase from fiscal 2023.
- AbbVie Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2023 was $1.62B, a 25.15% increase from fiscal 2022.
- AbbVie Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2022 was $1.30B, a 64.26% increase from fiscal 2021.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.06B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $1.78B 10-Q · filed 2026-08-03 | $2.46B derived: sum of 3 quarters · filed 2026-08-03 | $3.24B derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $722.00M 10-Q · filed 2026-05-08 | $1.40B derived: sum of 2 quarters · filed 2026-05-08 | $2.18B derived: sum of 3 quarters · filed 2026-05-08 | $3.04B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $681.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $1.46B derived: sum of 2 quarters · filed 2026-02-20 | $2.32B derived: sum of 3 quarters · filed 2026-08-03 | $2.87B 10-K · filed 2026-02-20 |
| 2025-09-30 | $776.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.64B derived: sum of 2 quarters · filed 2026-08-03 | $2.18B 10-Q · filed 2025-11-04 | $2.72B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $859.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $1.41B 10-Q · filed 2026-08-03 | $1.95B derived: sum of 3 quarters · filed 2026-08-03 | $2.53B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $549.00M 10-Q · filed 2026-05-08 | $1.09B derived: sum of 2 quarters · filed 2026-05-08 | $1.67B derived: sum of 3 quarters · filed 2026-05-08 | $2.15B derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $539.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $1.12B derived: sum of 2 quarters · filed 2026-02-20 | $1.60B derived: sum of 3 quarters · filed 2026-02-20 | $2.00B 10-K · filed 2026-02-20 |
| 2024-09-30 | $580.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.06B derived: sum of 2 quarters · filed 2025-11-04 | $1.46B 10-Q · filed 2025-11-04 | $1.94B derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-06-30 | $485.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $876.00M 10-Q · filed 2025-08-04 | $1.36B derived: sum of 3 quarters · filed 2026-02-20 | $1.84B derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-03-31 | $391.00M 10-Q · filed 2025-05-09 | $871.00M derived: sum of 2 quarters · filed 2026-02-20 | $1.36B derived: sum of 3 quarters · filed 2026-02-20 | $1.69B derived: sum of 4 quarters · filed 2026-02-20 |
| 2023-12-31 | $480.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $965.00M derived: sum of 2 quarters · filed 2026-02-20 | $1.30B derived: sum of 3 quarters · filed 2026-02-20 | $1.62B 10-K · filed 2026-02-20 |
| 2023-09-30 | $485.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $817.00M derived: sum of 2 quarters · filed 2024-11-04 | $1.14B 10-Q · filed 2024-11-04 | $1.46B derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-06-30 | $332.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $657.00M 10-Q · filed 2024-08-07 | $975.00M derived: sum of 3 quarters · filed 2025-02-14 | $1.38B derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-03-31 | $325.00M 10-Q · filed 2024-05-03 | $643.00M derived: sum of 2 quarters · filed 2025-02-14 | $1.05B derived: sum of 3 quarters · filed 2025-02-14 | $1.30B derived: sum of 4 quarters · filed 2025-02-14 |
| 2022-12-31 | $318.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | $726.00M derived: sum of 2 quarters · filed 2025-02-14 | $975.00M derived: sum of 3 quarters · filed 2025-02-14 | $1.30B 10-K · filed 2025-02-14 |
| 2022-09-30 | $408.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $657.00M derived: sum of 2 quarters · filed 2023-11-06 | $978.00M 10-Q · filed 2023-11-06 | $1.24B derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $249.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $570.00M 10-Q · filed 2023-08-07 | $834.00M derived: sum of 3 quarters · filed 2024-02-20 | $1.00B derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $321.00M 10-Q · filed 2023-05-05 | $585.00M derived: sum of 2 quarters · filed 2024-02-20 | $753.00M derived: sum of 3 quarters · filed 2024-02-20 | $978.00M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $264.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $432.00M derived: sum of 2 quarters · filed 2024-02-20 | $657.00M derived: sum of 3 quarters · filed 2024-02-20 | $789.00M 10-K · filed 2024-02-20 |
| 2021-09-30 | $168.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $393.00M derived: sum of 2 quarters · filed 2022-11-04 | $525.00M 10-Q · filed 2022-11-04 | $634.00M derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-06-30 | $225.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $357.00M 10-Q · filed 2022-08-04 | $466.00M derived: sum of 3 quarters · filed 2023-02-17 | $549.00M derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-03-31 | $132.00M 10-Q · filed 2022-05-06 | $241.00M derived: sum of 2 quarters · filed 2023-02-17 | $324.00M derived: sum of 3 quarters · filed 2023-02-17 | $400.00M derived: sum of 4 quarters · filed 2023-02-17 |
| 2020-12-31 | $109.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $192.00M derived: sum of 2 quarters · filed 2023-02-17 | $268.00M derived: sum of 3 quarters · filed 2023-02-17 | $321.00M 10-K · filed 2023-02-17 |
| 2020-09-30 | $83.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $159.00M derived: sum of 2 quarters · filed 2021-11-02 | $212.00M 10-Q · filed 2021-11-02 | $267.00M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-06-30 | $76.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-02 | $129.00M 10-Q · filed 2021-08-02 | $184.00M derived: sum of 3 quarters · filed 2022-02-18 | $196.00M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-03-31 | $53.00M 10-Q · filed 2021-05-07 | $108.00M derived: sum of 2 quarters · filed 2022-02-18 | $120.00M derived: sum of 3 quarters · filed 2022-02-18 | $287.00M derived: sum of 4 quarters · filed 2022-02-18 |
| 2019-12-31 | $55.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $67.00M derived: sum of 2 quarters · filed 2022-02-18 | $234.00M derived: sum of 3 quarters · filed 2022-02-18 | $234.00M 10-K · filed 2022-02-18 |
| 2019-09-30 | $12.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $179.00M derived: sum of 2 quarters · filed 2020-11-04 | $179.00M 10-Q · filed 2020-11-04 | $179.00M derived: sum of 4 quarters · filed 2021-02-19 |
| 2019-06-30 | $167.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | $167.00M 10-Q · filed 2020-08-04 | $167.00M derived: sum of 3 quarters · filed 2021-02-19 | $217.00M derived: sum of 4 quarters · filed 2021-02-19 |
| 2019-03-31 | $0.00 10-Q · filed 2020-05-08 | $0.00 derived: sum of 2 quarters · filed 2021-02-19 | $50.00M derived: sum of 3 quarters · filed 2021-02-19 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-19 | $50.00M derived: sum of 2 quarters · filed 2021-02-19 | $100.00M 10-K · filed 2021-02-19 | |
| 2018-09-30 | $50.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $100.00M 10-Q · filed 2019-11-06 | ||
| 2018-06-30 | $50.00M 10-Q · filed 2019-08-05 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $305.00M 10-K · filed 2020-02-21 | ||
| 2017-09-30 | $305.00M 10-Q · filed 2018-11-07 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-02-27 | |||
| 2014-12-31 | $24.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-20 | $24.00M derived: sum of 2 quarters · filed 2015-02-20 | $27.00M derived: sum of 3 quarters · filed 2015-02-20 | $164.00M 10-K · filed 2015-02-20 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $3.00M derived: sum of 2 quarters · filed 2014-11-07 | $140.00M 10-Q · filed 2014-11-07 | $140.00M derived: sum of 4 quarters · filed 2015-02-20 |
| 2014-06-30 | $3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $140.00M 10-Q · filed 2014-08-07 | $140.00M derived: sum of 3 quarters · filed 2015-02-20 | $140.00M derived: sum of 4 quarters · filed 2015-02-20 |
| 2014-03-31 | $137.00M 10-Q · filed 2014-05-09 | $137.00M derived: sum of 2 quarters · filed 2015-02-20 | $137.00M derived: sum of 3 quarters · filed 2015-02-20 | $137.00M derived: sum of 4 quarters · filed 2015-02-20 |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-20 | $0.00 derived: sum of 2 quarters · filed 2015-02-20 | $0.00 derived: sum of 3 quarters · filed 2015-02-20 | $131.00M 10-K · filed 2015-02-20 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $0.00 derived: sum of 2 quarters · filed 2013-11-12 | $131.00M 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $131.00M 10-Q · filed 2013-08-09 | ||
| 2013-03-31 | $131.00M 10-Q · filed 2013-05-08 | |||
| 2012-12-31 | $134.00M 10-K · filed 2014-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |